/i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2021/H/w/YbA657S3aYVfC0P9wboQ/g1-favicon.png){kind=small}
/i.s3.glbimg.com/v1/AUTH_da025474c0c44edd99332dddb09cabe8/internal_photos/bs/2023/1/X/nkkB7tSdirnIUbGhakCQ/favicon-o-globo.png){kind=small}
Overview
- Investigators carried out 24 search and seizure warrants across São Paulo, Rio de Janeiro, Bahia and Pernambuco, focusing on clinics, laboratories, businesses and residences tied to the suspected network.
- Police say the group ran an industrial‑scale scheme to fill, label and distribute tirzepatide outside sanitary standards, with online sales lacking basic quality, sterility and traceability controls.
- Sources with access to the inquiry told G1 and GloboNews that Unikka Pharma, linked to LCA Farmacêutica, allegedly imported more than 48 kg of tirzepatide from China and Canada without authorization, a volume they say could yield about 9.6 million doses.
- The case file tracks more than R$ 3.4 million in transfers between a company owned by physician‑influencer Gabriel Almeida and LCA, as agents examine whether he held a concealed stake in the pharmaceutical operation.
- Agents seized luxury cars, high‑end watches and an aircraft, while Almeida’s lawyers deny he manufactures or manipulates medicines and the doctor publicly argues individualized compounding can be lawful under Brazilian rules.